Pages that link to "Q41682696"
Jump to navigation
Jump to search
The following pages link to The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study (Q41682696):
Displaying 19 items.
- Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective (Q26746910) (← links)
- Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline (Q28076883) (← links)
- The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV). (Q37432877) (← links)
- Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir (Q37726632) (← links)
- Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial (Q38839784) (← links)
- Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues (Q39002714) (← links)
- Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. (Q39574126) (← links)
- Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus (Q39911124) (← links)
- In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered (Q40118666) (← links)
- Adverse events associated with ribavirin in sofosbuvir-based therapies for patients with chronic hepatitis C: A community practice experience (Q40125281) (← links)
- Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL-5 study (Q40215825) (← links)
- Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial). (Q40269112) (← links)
- Real-world effect of ribavirin on quality of life in HCV-infected patients receiving interferon-free treatment. (Q41928089) (← links)
- Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3. (Q47404164) (← links)
- Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C. (Q47547989) (← links)
- Chronic Hepatitis C Treatment with Daclatasvir Plus Asunaprevir Does Not Lead to a Decreased Quality of Life. (Q54258327) (← links)
- Health-related quality of life in patients with autoimmune hepatitis: A questionnaire survey (Q57031224) (← links)
- Daclatasvir and asunaprevir improves health-related quality of life in Japanese patients infected with hepatitis C virus (Q59349830) (← links)
- Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: A systematic literature review and meta-analysis (Q92544719) (← links)